FRM
SAGE

Fox Run Management’s Sage Therapeutics SAGE Stock Holding History

Fox Run Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-48,950
Closed -$266K – 1187
2024
Q4 		$266K Buy
48,950
+32,579
+199% +$199K 0.05% 676
2024
Q3 		$118K Sell
16,371
-24,376
-60% -$223K 0.03% 727
2024
Q2 		$443K Buy
+40,747
New +$522K 0.08% 451
2024
Q1 		– Sell
-12,556
Closed -$272K – 1023
2023
Q4 		$272K Buy
+12,556
New +$249K 0.07% 533
2023
Q3 		– Sell
-9,606
Closed -$452K – 957
2023
Q2 		$452K Buy
+9,606
New +$478K 0.13% 316
2023
Q1 		– Sell
-17,148
Closed -$654K – 899
2022
Q4 		$654K Buy
+17,148
New +$655K 0.26% 91
2022
Q3 		– Sell
-17,298
Closed -$559K – 798
2022
Q2 		$559K Buy
17,298
+10,863
+169% +$364K 0.28% 97
2022
Q1 		$213K Buy
+6,435
New +$242K 0.12% 397
2021
Q4 		– Sell
-6,597
Closed -$292K – 678
2021
Q3 		$292K Buy
+6,597
New +$303K 0.18% 245
2020
Q2 		– Sell
-12,359
Closed -$355K – 309
2020
Q1 		$355K Buy
+12,359
New +$716K 0.84% 14
2019
Q3 		– Sell
-1,808
Closed -$331K – 535
2019
Q2 		$331K Buy
+1,808
New +$309K 0.22% 189
2017
Q3 		– Sell
-3,400
Closed -$271K – 844
2017
Q2 		$271K Buy
+3,400
New +$246K 0.09% 446

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Fox Run Management's SAGE Position: Q1 2025 in Review

Fox Run Management sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 48,950 shares — an estimated $266K sold.

Fox Run Management first reported a position in SAGE in Q2 2017 and held it in 12 quarters. The position peaked at $654K in Q4 2022. 197 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Fox Run Management reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Fox Run Management sold 48,950 Sage Therapeutics shares in Q1 2025, an estimated $266K.
  • Fox Run Management first reported a position in Sage Therapeutics in Q2 2017 and held it in 12 quarters.
  • Fox Run Management's Sage Therapeutics position peaked at $654K in Q4 2022.
  • 197 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Fox Run Management's 13F filing for Q1 2025, filed 13 May 2025.